BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target
BMRN Analyst Ratings
BMRN Stock 12 Month Forecast
Average Price Target
MXN 1,732.01▲(69.64% Upside)Detailed List of Analyst Forecasts​
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem | Canaccord Genuity | MXN 2,152.57 | buy | 110.83%Upside | Reiterated | 10/29/26 | ||
| Jack Allen | Robert W. Baird | MXN 1,227.34 | hold | 20.21%Upside | Reiterated | 10/27/26 | ||
| Allison Bratzel | Piper Sandler | MXN 1,699.40 | buy | 66.44%Upside | Reiterated | 10/21/26 | ||
| Sean Laaman | Morgan Stanley | MXN 2,341.39→MXN 2,303.63 | buy | 125.62%Upside | Assigned | 10/21/26 | ||
| Phil Nadeau | TD Cowen | MXN 2,265.86 | buy | 121.93%Upside | Reiterated | 10/21/26 | ||
| Mohit Bansal | Wells Fargo | MXN 1,510.57 | buy | 47.95%Upside | Assigned | 10/20/26 | ||
| Jessica Fye | J.P. Morgan | MXN 1,623.87→MXN 1,642.75 | buy | 60.90%Upside | Assigned | 10/20/26 | ||
| Olivia Brayer | Cantor Fitzgerald | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | 10/19/26 | ||
| Joon Lee | UBS | MXN 2,152.57→MXN 1,661.63 | buy | 62.75%Upside | Assigned | 10/15/26 | ||
| Eliana Merle | Barclays | MXN 2,095.92→MXN 2,152.57 | buy | 110.83%Upside | Reiterated | 10/13/26 | ||
| Jason Gerberry | Bank of America Securities | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | 10/09/26 | ||
| Luca Issi | RBC Capital | MXN 1,170.69 | hold | 14.66%Upside | Reiterated | 10/08/26 | ||
| David Lebowitz | BMO Capital | MXN 1,831.57 | buy | 79.39%Upside | Reiterated | 10/06/26 | ||
| Debjit Chattopadhyay | Guggenheim | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | 09/17/26 | ||
| Eric Joseph | Citi | ― | buy | ― | Reiterated | 09/14/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem | 10/29/26 | MXN 2,152.57 | buy | 110.83%Upside | Reiterated | Canaccord Genuity | ||
| Jack Allen | 10/27/26 | MXN 1,227.34 | hold | 20.21%Upside | Reiterated | Robert W. Baird | ||
| Allison Bratzel | 10/21/26 | MXN 1,699.40 | buy | 66.44%Upside | Reiterated | Piper Sandler | ||
| Sean Laaman | 10/21/26 | MXN 2,341.39→MXN 2,303.63 | buy | 125.62%Upside | Assigned | Morgan Stanley | ||
| Phil Nadeau | 10/21/26 | MXN 2,265.86 | buy | 121.93%Upside | Reiterated | TD Cowen | ||
| Mohit Bansal | 10/20/26 | MXN 1,510.57 | buy | 47.95%Upside | Assigned | Wells Fargo | ||
| Jessica Fye | 10/20/26 | MXN 1,623.87→MXN 1,642.75 | buy | 60.90%Upside | Assigned | J.P. Morgan | ||
| Olivia Brayer | 10/19/26 | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | Cantor Fitzgerald | ||
| Joon Lee | 10/15/26 | MXN 2,152.57→MXN 1,661.63 | buy | 62.75%Upside | Assigned | UBS | ||
| Eliana Merle | 10/13/26 | MXN 2,095.92→MXN 2,152.57 | buy | 110.83%Upside | Reiterated | Barclays | ||
| Jason Gerberry | 10/09/26 | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | Bank of America Securities | ||
| Luca Issi | 10/08/26 | MXN 1,170.69 | hold | 14.66%Upside | Reiterated | RBC Capital | ||
| David Lebowitz | 10/06/26 | MXN 1,831.57 | buy | 79.39%Upside | Reiterated | BMO Capital | ||
| Debjit Chattopadhyay | 09/17/26 | MXN 1,623.87 | buy | 59.05%Upside | Reiterated | Guggenheim | ||
| Eric Joseph | 09/14/26 | ― | buy | ― | Reiterated | Citi |
Best Analysts Covering BioMarin Pharmaceutical
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.38% per trade.
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 46.51% of your transactions generating a profit, with an average return of -4.18% per trade.
Copying Cory Kasimov's trades and holding each position for 2 Years would result in 41.86% of your transactions generating a profit, with an average return of -2.07% per trade.
BMRN Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 26 | 25 | 16 | 17 | 26 |
| Buy | 6 | 7 | 10 | 17 | 17 |
| Hold | 10 | 13 | 14 | 15 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 42 | 45 | 40 | 49 | 56 |
In the current month, BMRN has received 43 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 1,732.01.
BMRN Financial Forecast
BMRN Earnings Forecast
Next quarter’s earnings estimate for BMRN is -MXN 1.57 with a range of -MXN 9.06 to MXN 4.53. The previous quarter’s EPS was MXN 22.66. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
BMRN Sales Forecast
Next quarter’s sales forecast for BMRN is MXN 19.30B with a range of MXN 18.86B to MXN 19.77B. The previous quarter’s sales results were MXN 18.81B. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.